Protein C or activated protein C-like molecules
US7226999B2 · kind B2 · utility
0Cited by
23References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 3, 2004 |
| Grant date | Jun 5, 2007 |
| Priority date | — |
| Expiry date | Dec 3, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y304/21069
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to novel conjugates between polypeptide variants of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and α1-antitrypsin. Consequently, such conjugates have an increased in vivo half-life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septic shock.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.